🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Guangzhou Jiayin Biotech clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Guangzhou Jiayin Biotech as lead sponsor. Synced 26 Sep 2026
6Current trials
1Recruiting now
0Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Guangzhou Jiayin Biotech is the lead sponsor of 6 current clinical trials in our China register. 1 is recruiting patients now. The most common phase is Observational. The most-studied condition is Wet Age-related Macular Degeneration.

ClinicalTrials.gov trials by status

  • Recruiting117%
  • Not yet open233%
  • By invitation350%

Trials by phase

  • Observational233%
  • Phase 1/2233%
  • Phase EARLY_PHASE1233%
01

Clinical trials sponsored by Guangzhou Jiayin Biotech

6 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Long-term Follow up Study of EXG102-031 in Participants With wAMD
NCT06859515 · ClinicalTrials.gov ↗ · Wet Age-related Macular Degeneration
Observational Recruiting 2025-03 China
To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)
NCT06888492 · ClinicalTrials.gov ↗ · Wet Age-related Macular Degeneration (wAMD), Wet Age-related Macular Degeneration
Phase EARLY_PHASE1 Not yet open 2025-03 China
The Safety and Efficacy of Intravenous EXG110 in Patients With Fabry Disease
NCT06819514 · ClinicalTrials.gov ↗ · Fabry Disease
Phase 1/2 Not yet open 2025-03 China
Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients with Spinal Muscular Atrophy Type 1
NCT05614531 · ClinicalTrials.gov ↗ · Spinal Muscular Atrophy Type I
Phase 1/2 By invitation 2023-02 China
A Long-term Follow-up Study Evaluating Intravenous Injection of EXG001-307 in Patients With Type 1 SMA
NCT06588803 · ClinicalTrials.gov ↗ · Spinal Muscular Atrophy
Observational By invitation 2025-03 China
Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients With Spinal Muscular Atrophy
NCT06888661 · ClinicalTrials.gov ↗ · Spinal Muscular Atrophy (SMA)
Phase EARLY_PHASE1 By invitation 2025-03 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Conditions in Guangzhou Jiayin Biotech trials

6 conditions
Wet Age-related Macular Degeneration2Spinal Muscular Atrophy Type I1Wet Age-related Macular Degeneration (wAMD)1Spinal Muscular Atrophy1Fabry Disease1Spinal Muscular Atrophy (SMA)1
03

By trial register

RegisterTrialsRecruiting
Clinical trials in China61

A trial with sites in more than one country appears in each of those registers.

04

Other sponsors in Wet Age-related Macular Degeneration

SponsorTrials
Kodiak Sciences1

Sponsors with the most current trials registered for this condition.

05

Questions about Guangzhou Jiayin Biotech trials

How many clinical trials does Guangzhou Jiayin Biotech sponsor?

Guangzhou Jiayin Biotech is the lead sponsor of 6 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Guangzhou Jiayin Biotech trials recruiting?

Yes. 1 of its 6 ClinicalTrials.gov trials is recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.